525 related articles for article (PubMed ID: 28084175)
21. Prostate cancer risk among users of digoxin and other antiarrhythmic drugs in the Finnish Prostate Cancer Screening Trial.
Kaapu KJ; Murtola TJ; Määttänen L; Talala K; Taari K; Tammela TL; Auvinen A
Cancer Causes Control; 2016 Feb; 27(2):157-64. PubMed ID: 26573846
[TBL] [Abstract][Full Text] [Related]
22. Initial choice of oral glucose-lowering medication for diabetes mellitus: a patient-centered comparative effectiveness study.
Berkowitz SA; Krumme AA; Avorn J; Brennan T; Matlin OS; Spettell CM; Pezalla EJ; Brill G; Shrank WH; Choudhry NK
JAMA Intern Med; 2014 Dec; 174(12):1955-62. PubMed ID: 25347323
[TBL] [Abstract][Full Text] [Related]
23. Metformin use and risk of prostate cancer: results from the REDUCE study.
Feng T; Sun X; Howard LE; Vidal AC; Gaines AR; Moreira DM; Castro-Santamaria R; Andriole GL; Freedland SJ
Cancer Prev Res (Phila); 2015 Nov; 8(11):1055-60. PubMed ID: 26353947
[TBL] [Abstract][Full Text] [Related]
24. Outcomes of Prostate-specific Antigen-based Prostate Cancer Screening Among Men Using Nonsteroidal Anti-inflammatory Drugs.
Murtola TJ; Vettenranta AM; Talala K; Taari K; Stenman UH; Tammela TLJ; Auvinen A
Eur Urol Focus; 2018 Dec; 4(6):851-857. PubMed ID: 28753870
[TBL] [Abstract][Full Text] [Related]
25. The influence of antidiabetic medications on the development and progression of prostate cancer.
Hitron A; Adams V; Talbert J; Steinke D
Cancer Epidemiol; 2012 Aug; 36(4):e243-50. PubMed ID: 22417708
[TBL] [Abstract][Full Text] [Related]
26. The impact of metformin use on the risk of prostate cancer after prostate biopsy in patients with high grade intraepithelial neoplasia.
Dell'Atti L; Galosi AB
Int Braz J Urol; 2018; 44(1):69-74. PubMed ID: 29211393
[TBL] [Abstract][Full Text] [Related]
27. Metformin significantly reduces incident prostate cancer risk in Taiwanese men with type 2 diabetes mellitus.
Tseng CH
Eur J Cancer; 2014 Nov; 50(16):2831-7. PubMed ID: 25201464
[TBL] [Abstract][Full Text] [Related]
28. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.
Ou HT; Chang KC; Li CY; Wu JS
Cardiovasc Diabetol; 2016 Mar; 15():41. PubMed ID: 26932742
[TBL] [Abstract][Full Text] [Related]
29. Blood glucose, glucose balance, and disease-specific survival after prostate cancer diagnosis in the Finnish Randomized Study of Screening for Prostate Cancer.
Murtola TJ; Sälli SM; Talala K; Taari K; Tammela TLJ; Auvinen A
Prostate Cancer Prostatic Dis; 2019 Sep; 22(3):453-460. PubMed ID: 30679762
[TBL] [Abstract][Full Text] [Related]
30. Prospective study of Type 2 diabetes mellitus, anti-diabetic drugs and risk of prostate cancer.
Häggström C; Van Hemelrijck M; Zethelius B; Robinson D; Grundmark B; Holmberg L; Gudbjörnsdottir S; Garmo H; Stattin P
Int J Cancer; 2017 Feb; 140(3):611-617. PubMed ID: 27770555
[TBL] [Abstract][Full Text] [Related]
31. Prostate cancer and PSA among statin users in the Finnish prostate cancer screening trial.
Murtola TJ; Tammela TL; Määttänen L; Huhtala H; Platz EA; Ala-Opas M; Stenman UH; Auvinen A
Int J Cancer; 2010 Oct; 127(7):1650-9. PubMed ID: 20073066
[TBL] [Abstract][Full Text] [Related]
32. Progression to insulin for patients with diabetes mellitus using the Texas Medicaid database.
Rascati KL; Richards KM; Lopez D; Cheng LI; Wilson JP
Clin Ther; 2011 Dec; 33(12):2016-20. PubMed ID: 22101160
[TBL] [Abstract][Full Text] [Related]
33. Antidiabetic therapy and the risk of heart failure in type 2 diabetic patients: an independent effect or confounding by indication.
Koro CE; Bowlin SJ; Weiss SR
Pharmacoepidemiol Drug Saf; 2005 Oct; 14(10):697-703. PubMed ID: 15654719
[TBL] [Abstract][Full Text] [Related]
34. Statin Use and Prostate Cancer Survival in the Finnish Randomized Study of Screening for Prostate Cancer.
Murtola TJ; Peltomaa AI; Talala K; Määttänen L; Taari K; Tammela TLJ; Auvinen A
Eur Urol Focus; 2017 Apr; 3(2-3):212-220. PubMed ID: 28753762
[TBL] [Abstract][Full Text] [Related]
35. Mortality outcomes of different sulphonylurea drugs: the results of a 14-year cohort study of type 2 diabetic patients.
Bo S; Castiglione A; Ghigo E; Gentile L; Durazzo M; Cavallo-Perin P; Ciccone G
Eur J Endocrinol; 2013 Jul; 169(1):117-26. PubMed ID: 23660643
[TBL] [Abstract][Full Text] [Related]
36. Risk of hypoglycaemia in users of sulphonylureas compared with metformin in relation to renal function and sulphonylurea metabolite group: population based cohort study.
van Dalem J; Brouwers MC; Stehouwer CD; Krings A; Leufkens HG; Driessen JH; de Vries F; Burden AM
BMJ; 2016 Jul; 354():i3625. PubMed ID: 27413017
[TBL] [Abstract][Full Text] [Related]
37. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study.
Masoudi FA; Inzucchi SE; Wang Y; Havranek EP; Foody JM; Krumholz HM
Circulation; 2005 Feb; 111(5):583-90. PubMed ID: 15699279
[TBL] [Abstract][Full Text] [Related]
38. Antidiabetic medication, statins and the risk of endometrioid endometrial cancer in patients with type 2 diabetes.
Arima R; Marttila M; Hautakoski A; Arffman M; Sund R; Ilanne-Parikka P; Kangaskokko J; Läärä E; Puistola U; Hinkula M
Gynecol Oncol; 2017 Sep; 146(3):636-641. PubMed ID: 28645427
[TBL] [Abstract][Full Text] [Related]
39. Associations between diabetes medication use and risk of second breast cancer events and mortality.
Calip GS; Yu O; Hoskins KF; Boudreau DM
Cancer Causes Control; 2015 Aug; 26(8):1065-77. PubMed ID: 25956271
[TBL] [Abstract][Full Text] [Related]
40. Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer.
He X; Esteva FJ; Ensor J; Hortobagyi GN; Lee MH; Yeung SC
Ann Oncol; 2012 Jul; 23(7):1771-80. PubMed ID: 22112968
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]